• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by 20/20 Biolabs Inc.

    6/23/26 5:02:46 PM ET
    $AIDX
    Precision Instruments
    Health Care
    Get the next $AIDX alert in real time by email
    DEFA14A 1 ea0295687-defa14a_2020bio.htm DEFINITIVE ADDITIONAL MATERIALS

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12

     

    20/20 Biolabs, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):  

     

    ☒No fee required
    ☐Fee paid previously with preliminary materials
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11.

     

     

     

     

     

     

     

    20/20 BIOLABS, INC.

    CONTROL ID:  
    REQUEST ID:  

     

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
    for the Annual Meeting of Stockholders

     

      DATE: Tuesday, August 18, 2026
      TIME: 10:00 A.m. Eastern time
      LOCATION: https://edge.media-server.com/mmc/go/AIDX2026AGM

     

    HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

    PHONE:

    Call toll free
    1-866-752-8683

    FAX:

    Send this card to
    202-521-3464

    INTERNET:
    https://www.iproxydirect.com/AIDX   
    and follow the on-screen instructions.

    EMAIL:

    proxy-ID@equiniti.com
    Include your Control ID in your email.

    This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/AIDX  
     
    If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy.  To facilitate timely delivery please make the request, as instructed above, before August 3, 2026.
     
    you may enter your voting instructions at https://www.iproxydirect.com/AIDX  
    until 11:59 pm eastern time August 17, 2026.

     

      The purposes of this meeting are as follows:   

      1. To elect the six (6) nominees named in the accompanying proxy statement to the board of directors, each to serve until our next annual meeting of stockholders or until such person shall resign, be removed or otherwise leave office;  
      2. To ratify the appointment of dbbmckennon as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;    
      3. To approve an amendment and restatement of our Second Amended and Restated Certificate of Incorporation to, among other things, increase the number of shares of common stock that the Company is authorized to issue from 50 million shares to 500 million shares;  
      4. To approve our 2026 Equity Incentive Plan;  
      5. To approve the adjournment of the Annual Meeting to a later date if necessary to solicit additional proxies if there are not sufficient votes to approve any of the foregoing proposals at the time of the Annual Meeting, or any adjournment or postponement thereof; and  
      6. to transact such other business as may properly come before the annual meeting or any adjustment thereof.  
         

     

    Pursuant to Securities and Exchange Commission rules, you are receiving this Notice that the proxy materials for the Annual Meeting are available on the Internet. Follow the instructions above to view the materials and vote or request printed copies.

    The board of directors has fixed the close of business on June 22, 2026 as the record date for the determination of stockholders entitled to receive notice of the Annual Meeting and to vote the shares of our common stock, par value $0.01 per share, they held on that date at the meeting or any postponement or adjournment of the meeting.

    The Board of Directors recommends that you vote ‘for’ all proposals above.
     
    Please note - This is not a Proxy Card - you cannot vote by returning this card

     

     

     

     

    Get the next $AIDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bergman Alan B.

    4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

    4/6/26 5:56:49 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form 4 filed by Zhou Jiming

    4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

    4/6/26 5:56:27 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Cohen Jonathan M

    4 - 20/20 Biolabs, Inc. (0001139685) (Issuer)

    3/4/26 5:48:56 PM ET
    $AIDX
    Precision Instruments
    Health Care

    $AIDX
    SEC Filings

    View All

    SEC Form DEFA14A filed by 20/20 Biolabs Inc.

    DEFA14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

    6/23/26 5:02:46 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form DEF 14A filed by 20/20 Biolabs Inc.

    DEF 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

    6/23/26 5:02:13 PM ET
    $AIDX
    Precision Instruments
    Health Care

    SEC Form PRE 14A filed by 20/20 Biolabs Inc.

    PRE 14A - 20/20 Biolabs, Inc. (0001139685) (Filer)

    6/1/26 4:40:25 PM ET
    $AIDX
    Precision Instruments
    Health Care

    $AIDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

    Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access to Management GAITHERSBURG, Md., June 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced the launch of a recurring monthly investor webinar series designed to keep shareholders and the broader investment community informed on the Company’s latest developments and progress. The inaugural web

    6/22/26 4:45:00 PM ET
    $AIDX
    Precision Instruments
    Health Care

    20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

    Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood ("MCED") test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services ("NDS"). NDS will provide ultrasound services and medical oversight in

    5/27/26 8:31:00 AM ET
    $AIDX
    Precision Instruments
    Health Care

    20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

    Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory if called upon to support or augment testing by public health laboratories. Early in the COVID-19 pandemic, 20/20 Biolabs was among the first companies in the U.S. to import, validate, and dis

    5/22/26 8:31:00 AM ET
    $AIDX
    Precision Instruments
    Health Care

    $AIDX
    Financials

    Live finance-specific insights

    View All

    20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

    State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent Strategic Wins Include Evexia Diagnostics Distribution Agreement, ROKIT Healthcare CKD License, and Commercial Launch of OneTest™ for Longevity GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20" or the "Company"), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the first quarter ended March

    5/20/26 4:05:00 PM ET
    $AIDX
    Precision Instruments
    Health Care